HN2008000360A - Dispersiones amorfas solidas - Google Patents

Dispersiones amorfas solidas

Info

Publication number
HN2008000360A
HN2008000360A HN2008000360A HN2008000360A HN2008000360A HN 2008000360 A HN2008000360 A HN 2008000360A HN 2008000360 A HN2008000360 A HN 2008000360A HN 2008000360 A HN2008000360 A HN 2008000360A HN 2008000360 A HN2008000360 A HN 2008000360A
Authority
HN
Honduras
Prior art keywords
dispersions
solid
amorph
piridazinol
benzodiacepine
Prior art date
Application number
HN2008000360A
Other languages
English (en)
Inventor
Jacobs Irwin
Higginns John
Guillot Micael
Franson Nancy
L Rocco William
Abu-Izza Khawla
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2008000360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of HN2008000360A publication Critical patent/HN2008000360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

LA PRESENTE INVENCION SE REFIERE A DISPERSIONES SOLIDAS AMORFAS DE 7 CLORO -N,N5 -TRIMETIL-4-OXO-3- FENIL3, 5-DIHIDRO 4H- PIRIDAZINOL[4,5-B] INDOL-1- ACETAMIDA, UN AGENTE FARMACOLOGICO QUE POSEE UN ALTA AFINIDAD POR LOS RECEPTORES DE BENZODIACEPINA DE TIPO PERIFERICO.
HN2008000360A 2005-08-29 2008-02-28 Dispersiones amorfas solidas HN2008000360A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
HN2008000360A true HN2008000360A (es) 2011-05-31

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008000360A HN2008000360A (es) 2005-08-29 2008-02-28 Dispersiones amorfas solidas

Country Status (31)

Country Link
US (1) US7713548B2 (es)
EP (1) EP1926476B1 (es)
JP (1) JP5026426B2 (es)
KR (1) KR20080061354A (es)
CN (1) CN101272767B (es)
AR (1) AR055615A1 (es)
AU (1) AU2006285111B8 (es)
BR (1) BRPI0615609A2 (es)
CA (1) CA2619438A1 (es)
CR (1) CR9750A (es)
DK (1) DK1926476T3 (es)
EA (1) EA015715B1 (es)
EC (1) ECSP088203A (es)
ES (1) ES2414434T3 (es)
HK (1) HK1124785A1 (es)
HN (1) HN2008000360A (es)
HR (1) HRP20130533T1 (es)
IL (1) IL189587A (es)
MA (1) MA29783B1 (es)
ME (1) ME01560B (es)
NO (1) NO20081364L (es)
NZ (1) NZ566313A (es)
PL (1) PL1926476T3 (es)
PT (1) PT1926476E (es)
RS (1) RS52914B (es)
SI (1) SI1926476T1 (es)
TN (1) TNSN08069A1 (es)
TW (1) TWI398250B (es)
UA (1) UA93517C2 (es)
WO (1) WO2007027494A2 (es)
ZA (1) ZA200801893B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012945A (es) 2006-04-07 2009-01-15 Vertex Pharma Moduladores de transportadores de cartucho de union a adenosina-trifosfato celular (atp).
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
US20110021567A1 (en) * 2008-03-11 2011-01-27 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
KR20110052640A (ko) * 2008-08-18 2011-05-18 사노피-아벤티스 유.에스. 엘엘씨 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디하이드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 다형체의 제조방법
CN109081804B (zh) * 2010-03-25 2021-12-10 弗特克斯药品有限公司 环丙烷甲酰胺的固体形式
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
EP3039599A4 (en) * 2013-08-30 2017-04-19 Hewlett-Packard Enterprise Development LP Comparing real-time movements to pattern profile background
EP3120871B1 (en) * 2014-03-18 2023-06-28 Takeda Pharmaceutical Company Limited Solid dispersion
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
WO2017148837A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CA3066046A1 (en) * 2017-07-04 2019-01-10 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
ATE400251T1 (de) 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
CR9750A (es) 2008-06-18
IL189587A0 (en) 2008-08-07
HRP20130533T1 (en) 2013-07-31
AU2006285111B2 (en) 2012-04-26
WO2007027494A2 (en) 2007-03-08
AU2006285111B8 (en) 2012-05-17
TWI398250B (zh) 2013-06-11
BRPI0615609A2 (pt) 2011-05-24
UA93517C2 (en) 2011-02-25
NZ566313A (en) 2011-04-29
HK1124785A1 (es) 2009-07-24
KR20080061354A (ko) 2008-07-02
EP1926476A2 (en) 2008-06-04
MA29783B1 (fr) 2008-09-01
PL1926476T3 (pl) 2013-08-30
SI1926476T1 (sl) 2013-07-31
JP5026426B2 (ja) 2012-09-12
AU2006285111A1 (en) 2007-03-08
ES2414434T3 (es) 2013-07-19
EP1926476B1 (en) 2013-04-10
AR055615A1 (es) 2007-08-29
PT1926476E (pt) 2013-07-10
EA015715B1 (ru) 2011-10-31
ZA200801893B (en) 2009-08-26
US20080160080A1 (en) 2008-07-03
TNSN08069A1 (en) 2009-07-14
ECSP088203A (es) 2008-06-30
CA2619438A1 (en) 2007-03-08
US7713548B2 (en) 2010-05-11
CN101272767B (zh) 2012-08-29
TW200727902A (en) 2007-08-01
ME01560B (me) 2014-04-20
CN101272767A (zh) 2008-09-24
EA200800713A1 (ru) 2008-10-30
WO2007027494A3 (en) 2007-08-02
NO20081364L (no) 2008-04-03
IL189587A (en) 2012-12-31
JP2009506114A (ja) 2009-02-12
RS52914B (en) 2014-02-28
DK1926476T3 (da) 2013-07-01

Similar Documents

Publication Publication Date Title
HN2008000360A (es) Dispersiones amorfas solidas
AR052190A1 (es) Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas
CR10157A (es) Compuestos químicos
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
TW200716552A (en) Novel thiophene derivatives
CR9786A (es) Compuestos de bencimidazol-tiofeno
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CR8428A (es) Agente endoparasiticidas para la administracion topica
ATE409697T1 (de) 1,1a,5,5a-tetrahydro-3-thia- cyclopropaäaüpentalene: trizyklische thiophenderivate als s1p1/edg1-rezeptor-agonisten
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
CR9364A (es) Agentes endoparasiticidas
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
AR064219A1 (es) Cuerpo moldeado que contiene titanio
AR072426A1 (es) Uso de nifurtimox para el tratamiento de enfermedades causadas por tricomonadida
GT200600094A (es) Reduccion de la digeribilidad del fosforo
CL2008000949A1 (es) Compuestos derivados de 2,3-benzodiazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos psicoticos.
CA113787S (en) Lever
SV2007002216A (es) Nueva combinacion antiparasitaria de principios activos ref. bhc041312-sv